Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.

Cancer treatment reviews - 1 Feb 2017

Martinelli Erika, Morgillo Floriana, Troiani Teresa, Ciardiello Fortunato

Abstract excerpt

The mitogen-activated protein kinases (MAPKs) mediate intracellular signals activated by a wide variety of extracellular stimuli. The activation of the RAS-RAF-MEK-MAPK cascade culminates in the regulation of gene transcription promoting cancer cell proliferation, survival, migration and angiogenesis. MEK (mitogen-activated protein kinase kinase-MAPKK) 1/2 is a transducer of the growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to MAP Kinase Kinase 1
Share to MAP Kinase Kinase 2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Metabolic Networks and Pathways

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins B-raf

Share to raf Kinases

Share to ras Proteins

Source

Identifiers

PMID: 28073102
DOI: 10.1016/j.ctrv.2016.12.001

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.PMID 28073102Read ↗

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapySemantic proximity Read ↗

RAS/RAF/MEK Inhibitors in OncologySemantic proximity Read ↗

ERK inhibition overcomes acquired resistance to MEK inhibitors.Semantic proximity Read ↗

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read ↗

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.Semantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancerSemantic proximity Read ↗

MEK and RAF inhibitors for BRAF-mutated cancersSemantic proximity Read ↗

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studiesSemantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

BRAF mutation predicts sensitivity to MEK inhibition.Semantic proximity Read ↗

The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.